Patent Absurdity: When Innovation Protection Becomes Theater

The official version of patent law is elegant in its simplicity. An inventor files a patent, discloses their method publicly, and receives a limited monopoly in return. The government gets a searchable body of technical knowledge. The inventor gets 20 years to commercialise. Everyone benefits. Society advances.

The practice diverges from the theory at almost every interesting point.

Between 2005 and 2023, litigation filed by non-practicing entities (NPEs) grew by over 500%. These are companies that hold patents but manufacture nothing with them. NPE suits now account for roughly 63% of all US patent lawsuits. The entities filing those suits are sometimes called patent assertion entities, or PAEs. The less charitable term is patent trolls. They prefer NPEs. The terminology matters less than the mechanics.

The mechanics follow a specific sequence. An NPE acquires a portfolio of broadly written patents, often for cents on the dollar from bankrupt companies or prolific individual filers. It then identifies companies whose products might, with the right claim construction argument, be said to infringe one or more claims. The NPE sends a demand letter. The demand is calibrated to sit below the estimated cost of defending a patent case through trial, which in the US typically runs between $2M and $5M in legal fees. The median NPE settlement is closer to $300,000. Most defendants pay. Given the numbers, it is rational to pay.

Why 87% of Cases Settle Before Anyone Sees a Courtroom

Settlement tracks rational self-interest. The litigation system creates asymmetric cost structures that make fighting expensive even when the defendant is in the right. A company that prevails at trial after three years and $4M in legal fees has won in the technical sense. The P&L tells a different story.

This is where the model's durability comes from. The NPE carries lower marginal costs per suit than any defendant. It has no products to disrupt, no customers to reassure, no sales pipeline threatened by the proceedings. A manufacturer, a software firm, or a medical device company carries all of those things. The NPE's leverage comes from its productive absence.

For roughly fifteen years, the Eastern District of Texas functioned as the preferred venue for NPE plaintiffs. Favourable procedural rules, jury pools sympathetic to patent holders, and expedited trial schedules made it an exceptionally reliable venue for plaintiff-side litigation. At its peak, close to 40% of all US patent cases were filed there. The Supreme Court's 2017 decision in TC Heartland LLC v. Kraft Foods Group Brands tightened venue rules and dispersed filings. Forum dynamics haven't disappeared. They've redistributed.

Companies That Get Targeted

Assuming NPE targets are primarily large technology companies is worth examining carefully. Intellectual Ventures, the NPE aggregator that accumulated over 70,000 patents before its model began unwinding after 2015, spent years focused on Microsoft, Apple, and Motorola. Those cases generated headlines. They were also exceptional.

The majority of NPE litigation targets smaller companies. A 2021 analysis of patent assertion patterns found that over 50% of NPE defendant firms had annual revenues below $10 million. These are the targets where the economics work most cleanly for an NPE. Small enough that a $150,000 settlement is a meaningful disruption, substantial enough to have some resources, with product sets touching enough overlapping claims to give the assertion surface area.

Independent software developers encountered this dynamic after Lodsys, an NPE, began sending demand letters to individual iOS app developers in 2011, asserting that in-app purchase functionality built on Apple's own APIs infringed its patents. Apple eventually stepped in to defend its developer community under its existing patent license. Most small developers had no such shield. Many settled quickly. The absorbed lesson across the industry was that patent exposure is a fixed overhead of building in software, a tariff extracted on the basis of operating in a densely patented space where someone has already mapped the territory.

The practical response to NPE exposure involves four areas of assessment. Running all four annually takes less time than most companies spend on trademark renewals, and the asymmetry between those two risk categories doesn't favour the company that only maintains the latter.

What the Data Shows About Patent Troll Litigation Strategy Outcomes

The 87% settlement rate gets cited as evidence that the NPE model works. In the narrow sense that it generates recurring revenue for the entities running it, it does. The underlying validity rate tells a sharper story about what is being contested.

When NPE cases reach trial or proceed through Inter Partes Review (IPR) at the USPTO, the rate at which asserted claims are found both valid and infringed sits well below 1% of total filed cases. That ratio explains the settlement logic from the NPE's side. A model generating revenue at an 87% clip with near-zero trial wins is a model built on cost asymmetry, with legal merit arriving late and rarely.

Congress tried to address this. The America Invents Act (2011) created the IPR mechanism specifically to allow defendants to challenge patent validity before the Patent Trial and Appeal Board (PTAB) as an alternative to district court proceedings. For defendants with strong prior art arguments, IPR has been a meaningful tool. A 2023 PTAB statistics report showed IPR petition institution rates above 60%, with a significant share of instituted reviews resulting in claim cancellation or amendment.

The system has been partially recalibrated. The 63% NPE share of patent litigation hasn't moved accordingly. What has shifted is the cost-benefit calculus for defendants who know to use the tools available, which is exactly where your four-part annual review fits.

The patent system is functioning as designed. The design just has more stakeholders than the inventors who first lobbied for it. Operators who treat IP exposure as a legal department concern rather than an operational variable will keep discovering this at the worst possible moment (which, consistently, is after the demand letter arrives).

A company or individual that holds patents but manufactures no products and provides no services based on those patents. Covers a spectrum from universities and research labs to pure-play litigation vehicles.